Recerca

Àrea 3

Fisiopatologia i tractament de l’ascites i del trastorn de la funció renal a la cirrosi hepàtica

Articles de l'any 2010
Original

Originals publicats: 28

Factor d'impacte: mitjana: 8.61, total: 240.99

  • Cigarette smoking and chronic liver diseases

    Altamirano J, Bataller R
    GUT. 2010; 59: 1159-1162. IF: 9.357

  • The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis

    Albillos A, Nieto M, Ubeda M, Munoz L, Fraile B, Reyes E, Lledo L, Blanco I, Pastor O, Salas C, Lario M, Monserrat J, Bataller R, Alvarez-Mon M
    GUT. 2010; 59: 943-952. IF: 9.357

  • Inactivation of extrahepatic vascular Akt improves systemic hemodynamics and sodium excretion in cirrhotic rats

    Fernandez-Varo G, Melgar-Lesmes P, Casals G, Pauta M, Arroyo V, Morales-Ruiz M, Ros J, Jimenez W
    J HEPATOL. 2010; 53: 1041-1048. IF: 7.818

  • Effects of a selective vasopressin V-2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

    Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M
    J HEPATOL. 2010; 53: 283-290. IF: 7.818

  • Matrix Metalloproteinase 2 in Reduced-Size Liver Transplantation: Beyond the Matrix

    Padrissa-Altes S, Zaouali MA, Franco-Gou R, Bartrons R, Boillot O, Rimola A, Arroyo V, Rodes J, Peralta C, Rosello-Catafau J
    AM J TRANSPLANT. 2010; 10: 1167-1177. IF: 6.433

Revisió

Revisions publicades: 3

Factor d'impacte: mitjana: 4.15, total: 12.46

  • Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives

    Sola E, Gines P
    J HEPATOL. 2010; 53: 1135-1145. IF: 7.818

  • Refractoryascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis

    Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS
    LIVER INT. 2010; 30: 937-947. IF: 2.987

Editorials

Editorials publicades: 1

Factor d'impacte: mitjana: 1.66, total: 1.66

  • Resolution of Acute Inflammation and the Role of Lipid Mediators

    Claria J
    THESCIENTIFICWORLDJO. 2010; 10: 1553-1555. IF: 1.658

Guies clíniques

Guies clínique publicades: 1

Factor d'impacte: mitjana: 7.82, total: 7.82

  • EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver

    Gines P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, Merkel C, Ring-Larsen H, Bernardi M, Garcia-Tsao G, Hayers P
    J HEPATOL. 2010; 53: 397-417. IF: 7.818

Més articles
Tesis
  • Fisiopatologia del edema y de la formacion de ascitis en la cirrosis hepática experimental

    Doctorand: Pedro Melgar Lesmes,
    Director/s: Jimenez W

  • Investigación de nuevas estrategias terapeúticas para la inflamación y la fibrosis hepática.

    Doctorand: Montserrat Moreno Sanchez,
    Director/s: Bataller R

Més tesis
Patents
  • Terlipressin como tratamiento cirrosis y sindrome hepatorenal

    UNIV BARCELONA